AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prone position ventilation technique
Description: 1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two samples of saliva
Description: 1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two samples of saliva
Description: 1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation
Study NCT01674218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
Study NCT01382888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin 2,400 IU /ml Cutaneous Spray
Description: Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
Study NCT01382888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cutaneous Spray
Description: Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
Study NCT01217294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided fascia iliaca block
Description: Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
Study NCT01217294 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: spinal morphine
Description: Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
Study NCT03816475 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
Study NCT00629018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ autologous stem cell transplantation
Description: Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
Study NCT00629018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Stimulation
Description: Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
Study NCT00629018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC therapy
Description: In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
Study NCT02561117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Administration once daily
Study NCT02561117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Administration once daily
Study NCT02608411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ197
Study NCT01107691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of resistance offered in training
Description: to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
Study NCT00652340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib/erlotinib
Description: apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert
Study NCT00652340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib/placebo
Description: erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing behaviour
Description: Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing behaviour
Description: Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study of the food bolus
Description: 2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of the food bolus
Description: 2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthfeel
Description: Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
Study NCT03227887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthfeel
Description: Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
Study NCT02130063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside 1000 (Monofer®)
Study NCT02779972 — intervention group
Intervention type: OTHER
Intervention: Echo stress test
Description: Echo stress test
Study NCT01760772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-9
Description: Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
Study NCT01760772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Constant infusion of GLP-1 at 0.3 pmol/kg/min
Study NCT01760772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Constant infusion
Study NCT02216448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training knee simulator
Description: Training in a lab on a virtual reality knee arthroscopy simulator
Study NCT02216448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OR Training
Description: Training on diagnostic knee arthroscopy in the OR
Study NCT02130063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose (Venofer®)
Study NCT00779012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
Study NCT03113981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Implanting THA grafted with PolyNass or not
Study NCT03113981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Implanting THA grafted with PolyNass or not
Study NCT02718092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Stent
Description: Subjects who are randomized to this arm will receive a plastic stent
Study NCT02718092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axios Fully Covered Self Expanding Metal Stent
Description: Subjects who are randomized to this arm will receive the Axios FCEMS
Study NCT01397942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
Study NCT01971385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squaric Acid solution
Study NCT01971385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study NCT04079075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will.
Study NCT04079075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
Study NCT04079075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared.
Study NCT04079075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaption to memory loss
Description: This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
Study NCT04079075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis of hearing impairment
Description: Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
Study NCT01546688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide at targeted daily doses of 100-500 mg/day
Description: Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
Study NCT01546688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administered to match targeted daily doses of 100-500 mg/day
Description: matching placebo
Study NCT00648700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets 300 μg
Description: 2x300mcg, single dose fasting
Study NCT00648700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothroid® Tablets 300 μg
Description: 2x300mcg, single dose fasting
Study NCT03863808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks.
Study NCT03769792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and faeces tests
Description: During V0 - Laboratory tests, particularly for calprotectin concentration assessment
Study NCT03769792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance spectroscopy test
Description: During V1 - the electrical impedance of pelvic floor muscles will be measured
Study NCT03769792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Full gynecological and proctological examination
Description: During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
Study NCT03863808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises
Description: Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
Study NCT00544037 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Standard Therapy for Multiple Sclerosis
Study NCT04705506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin
Description: We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
Study NCT03769792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transanal ultrasonography
Description: During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
Study NCT03769792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
Study NCT02185040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: 0.3 mg oral capsules once every other day with or without food
Study NCT02185040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: Subjects will receive 0.3 mg oral capsules every day with or without food
Study NCT02185040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
Study NCT02185040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 oral capsule 0.6 mg QD with or without food
Study NCT02185040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo daily
Study NCT01163409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise training comprises aerobic and strength training
Study NCT01163409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture involves two sessions per week, during 14 weeks.
Study NCT00623753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EnvDNA, PolyEnv1, EnvPro
Description: Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
Study NCT03734601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
Study NCT03734601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: Given intravenous (IV), Dose 1.5 mg/kg x 5 days
Study NCT03734601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
Study NCT03734601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
Study NCT03734601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Description: 9 x 120 cGy over 11 days
Study NCT01163409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise, Acupuncture and Fibromyalgia
Description: Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
Study NCT00156962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa DT
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
Study NCT00156962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa RB
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
Study NCT04705506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
Study NCT01760343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Berinert
Description: Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
Study NCT01163409 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Exercise, Acupuncture and Fibromyalgia
Description: Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
Study NCT04090593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education 101: Mobile Health Education Tool
Description: Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.